Abbott Laboratories (ABT) : Rosenbaum Jay D. scooped up 2,130 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 20, 2016. The investment management firm now holds a total of 37,005 shares of Abbott Laboratories which is valued at $1,631,180.Abbott Laboratories makes up approximately 0.30% of Rosenbaum Jay D.’s portfolio.
Abbott Laboratories opened for trading at $43.72 and hit $44.17 on the upside on Friday, eventually ending the session at $44.08, with a gain of 0.46% or 0.2 points. The heightened volatility saw the trading volume jump to 46,91,801 shares. Company has a market cap of $64,941 M.
Other Hedge Funds, Including , Murphy Capital Management Inc reduced its stake in ABT by selling 1,150 shares or 11.16% in the most recent quarter. The Hedge Fund company now holds 9,151 shares of ABT which is valued at $403,376. Abbott Laboratories makes up approx 0.06% of Murphy Capital Management Inc’s portfolio.Country Club Trust Company N.a. reduced its stake in ABT by selling 1,600 shares or 17.31% in the most recent quarter. The Hedge Fund company now holds 7,644 shares of ABT which is valued at $331,826. Abbott Laboratories makes up approx 0.05% of Country Club Trust Company N.a.’s portfolio.Central Trust Co boosted its stake in ABT in the latest quarter, The investment management firm added 3,287 additional shares and now holds a total of 168,510 shares of Abbott Laboratories which is valued at $7,315,019. Abbott Laboratories makes up approx 0.57% of Central Trust Co’s portfolio.New England Research Management reduced its stake in ABT by selling 800 shares or 5.02% in the most recent quarter. The Hedge Fund company now holds 15,127 shares of ABT which is valued at $642,595. Abbott Laboratories makes up approx 0.55% of New England Research Management’s portfolio.
On the company’s financial health, Abbott Laboratories reported $0.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Apr 20, 2016. Analyst had a consensus of $0.39. The company had revenue of $4885.00 million for the quarter, compared to analysts expectations of $4777.68 million. The company’s revenue was down -.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.47 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Company shares were Reiterated by RBC Capital Mkts on Apr 11, 2016 to “Outperform”, Firm has raised the Price Target to $ 48 from a previous price target of $45 .Shares were Reiterated by RBC Capital Mkts on Jan 29, 2016 to “Outperform” and Lowered the Price Target to $ 45 from a previous price target of $51 .
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.